Changes in Beneficial Ownership · 4
Liquidia Corporation
LQDANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2627530-4_4seq1.xml
Filing details
- Report period
- 2026-10-09
- Issuer
- Liquidia Corp
- Issuer CIK
- 0001819576
- Trading symbol
- LQDA
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Kaseta Michael
- Reporting owner CIK
- 0001724346
- Relationship
- Officer
- Officer title
- CFO and COO
- Address
- 419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC, 27560
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-09 | M · Form 4 | 5,828[F2] | A | [F1] | 352,037[F3] | D |
| Common Stock | 2026-10-09 | M · Form 4 | 7,049[F4] | A | [F1] | 359,086[F3] | D |
| Common Stock | 2026-10-12 | S · Form 4[F5] | 18,938[F6] | D | 28.48 | 340,148[F3] | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- S · Form 4
- Sale on the market or privately
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Units | [F1] | 2026-10-09 | M · Form 4 | 5,828 | D | 0 | [F1] | [F1] | Common Stock | 5,828 | 29,140 | D |
| Performance Stock Units | [F1] | 2026-10-09 | M · Form 4 | 7,049 | D | 0 | [F1] | [F1] | Common Stock | 7,049 | 63,448 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Performance stock units ("PSUs") convert into common stock on a one-for-one basis.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
- F2
- On January 11, 2024, the Reporting Person was granted 93,250 PSUs with 25% of the PSUs vesting on January 11, 2025 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 64,110 have vested as of the date of this Form 4.↩ 1
- F3
- Includes (i) 7,792 unvested restricted stock units ("RSUs") of the 124,667 RSUs granted to the Reporting Person on January 11, 2023, (ii) 29,140 unvested RSUs and 15,625 unvested RSUs of the 93,250 RSUs and 50,000 RSUs granted to the Reporting Person on January 11, 2024 and January 15, 2024, respectively, (iii) 63,448 unvested RSUs of the 112,797 RSUs granted to the Reporting Person on January 11, 2025, (iv) 59,320 RSUs granted to the Reporting Person on January 16, 2026, none of which have vested as of the date of this Form 4 and (v) 3,054 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan ("ESPP").↩ 1↩ 2↩ 3
- F4
- On January 11, 2025, the Reporting Person was granted 112,797 PSUs with 25% of the PSUs vesting on January 11, 2026 and the remaining PSUs vesting ratably on a quarterly basis over three years thereafter. Of those PSUs, a total of 49,349 have vested as of the date of this Form 4.↩ 1
- F5
- Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.↩ 1
- F6
- These shares of common stock were sold to cover taxes associated with the settlement of RSUs and PSUs that were initially granted to the Reporting Person on January 11, 2023, January 11, 2024, January 15, 2024 and January 11, 2025.↩ 1
Signature 1
- Signed
- /s/ Michael Kaseta
- Date
- 2026-10-13
Company context
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of YUTREPIA® (treprostinil) inhalation powder, a drug approved in 2025 for the treatment of PAH. YUTREPIA is currently under development for other indications, including SSc-RP and PH-COPD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. To learn more about Liquidia, please visit www.liquidia.com.